- Home
- INSM vs AEE Comparison
INSM vs AEE Comparison
Compare INSM & AEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- AEE
- Stock Information
- Founded
- INSM 1988
- AEE 1901
- Country
- INSM United States
- AEE United States
- Employees
- INSM N/A
- AEE N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- AEE Power Generation
- Sector
- INSM Health Care
- AEE Utilities
- Exchange
- INSM Nasdaq
- AEE Nasdaq
- Market Cap
- INSM 29.0B
- AEE 27.3B
- IPO Year
- INSM 2000
- AEE N/A
- Fundamental
- Price
- INSM $162.43
- AEE $103.94
- Analyst Decision
- INSM Strong Buy
- AEE Buy
- Analyst Count
- INSM 19
- AEE 9
- Target Price
- INSM $152.71
- AEE $105.44
- AVG Volume (30 Days)
- INSM 2.2M
- AEE 1.5M
- Earning Date
- INSM 10-30-2025
- AEE 11-05-2025
- Dividend Yield
- INSM N/A
- AEE 2.74%
- EPS Growth
- INSM N/A
- AEE 2.91
- EPS
- INSM N/A
- AEE 4.55
- Revenue
- INSM $398,105,000.00
- AEE $8,119,000,000.00
- Revenue This Year
- INSM $32.44
- AEE $16.32
- Revenue Next Year
- INSM $123.99
- AEE $6.05
- P/E Ratio
- INSM N/A
- AEE $22.81
- Revenue Growth
- INSM 21.15
- AEE 17.75
- 52 Week Low
- INSM $60.40
- AEE $85.27
- 52 Week High
- INSM $163.22
- AEE $105.67
- Technical
- Relative Strength Index (RSI)
- INSM 80.62
- AEE 61.06
- Support Level
- INSM $156.87
- AEE $103.22
- Resistance Level
- INSM $163.22
- AEE $105.67
- Average True Range (ATR)
- INSM 4.29
- AEE 1.28
- MACD
- INSM 0.73
- AEE 0.26
- Stochastic Oscillator
- INSM 94.51
- AEE 76.24
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.